Merus jumps on Genmab's $8 billion buyout deal

Genmab A/S

29/09/2025 11:12

** U.S.-listed shares of Merus NV 2GH.F, MRUS.O rise 38% to $95.20 premarket

** Denmark's Genmab GMAB.CO will acquire Dutch biotech firm Merus in an all-cash deal valued at $8 billion, the companies say

** Genmab will pay $97 per share, representing a 41% premium over Merus' Friday closing price

** "We see the proposed acquisition as making strategic sense and offering a path to growth," especially as Genmab prepares for the loss of exclusivity on its cancer drug Darzalex IV, J.P.Morgan analysts say

** The deal is expected to close in early 2026

** As of last close, MRUS up 63.8% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))